Loading stock data…
APVO
$4.76-0.07 (-1.55%)
Market ClosedLast close Jun 9
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aptevo Therapeutics Inc. in the Healthcare sector is trading at $4.76. Wall Street consensus targets $21.00 (1 analysts), implying a +341.2% move over the next 12 months. The stock is currently near its 52-week low of $3.80, remaining 67.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +341.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.76
Potential Downside
0%
Whystock Fair Value$4.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$21.00+341.2%
Range$21.00 – $21.00
Fundamentals
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using A...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-226.11%
Volume
Today's trading volume
16,542
Recent News
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds
US stocks look set to open higher Thursday following a lower-than-expected jobless claims report and